Menu
Recruiting NCT03827031

Impact of Mulstidisciplinary Medication Assessment Review in Surgery Departments

No phase Interventional Chronic Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Mutlidisciplinary medication Review (MMR), Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up.
Who it may be relevant to
Registry conditions: Chronic Disease. Basic parameters: from 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
France
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Implementation and Impact of Multidisciplinary Medication Review in Surgery Departments on Medication Management of Elderly Patients

Overview

The presence of a clinical pharmacist (for their pharmacological expertise) and a general practitioner (for their somatic expertise) in surgery departments would contribute to improve the management of medications in elderly patients.

Interventions

  • Other Mutlidisciplinary medication Review (MMR)
    The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community pharamcist to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Three months after discharge, the patient's community
  • Other Mutlidisciplinary medication Review (MMR) with community pharmacist follow-up
    Multidisciplinary medication review (MMR) The clinical pharmacist performs medication reconciliation and pharmaceutical analysis. The physician performs a clinical examination and analysis of the medical record. Both participate in a collaborative interview. The hospital physician calls the community physician to discuss proposed changes on the order and to establish a new prescription. At the end of the stay, the clinical pharmacist will conduct an exit interview with the patient. Community fo

Primary outcome measures

  • Change in iatrogenic drug risk in intervention groups versus control group [Time frame: 3 months after hospitalization]
Secondary outcome measures (12)
  • Proportion of proposed medication modifications made by the clinical pharmacist accepted by the clinical doctor during the Multidisciplinary Medication Review in the experimental groups [Time frame: Hospital discharge (maximum 30 days)]
  • Number of potentially inappropriate medications per patient in each group [Time frame: Hospital discharge (maximum 30 days)]
  • Proportion of proposed medication modifications made by the collaborative team accepted and/or made permanent [Time frame: 3 months after hospital discharge]
  • Number of potentially inappropriate medications per patient in each group [Time frame: 3 months after hospital discharge]
  • Time required for Multidisciplinary Medication Review in the interventional groups (B1 and B2) [Time frame: Hospital discharge (maximum 30 days)]
  • Time required for ransmitting multidisciplinary correspondence documents in B2 group [Time frame: Hospital discharge (maximum 30 days)]
  • Number of multidisciplinary correspondence documents sent to the community acotors in B2 group [Time frame: Hospital discharge (maximum 30 days)]
  • Description of mode of diffusion of multidisciplinary correspondence documents in the B2 group [Time frame: Hospital discharge (maximum 30 days)]
  • Description of reason for non-transmission of multidisciplinary correspondence documents in the B2 group [Time frame: Hospital discharge (maximum 30 days)]
  • Rate of patients for whom a follow-up review of proposed medication changes has been performed by the pharmacist in the B2 group [Time frame: 2 months post discharge]
  • Number of multidisciplinary correspondence documents transmitted by community pharmacist in group B2 [Time frame: 2 months post hospital discharge]
  • Rate of patients with at least one rehospitalization in each group [Time frame: 3 months after hospital discharge]

Eligibility criteria

Inclusion criteria

  • The patient (or their representative) has given his consent and signed the consent form.
  • The patient is affiliated to a health insurance programme.
  • The patient is at least 65 years old (≥) treated by at least (≥) five medications for at least (≥) 6 months
  • The patient is available for a follow-up of 3 months.
  • The patient is hospitalized in the surgery department.
  • Patient with a Trivalle score greater than or equal to 2 (≥).
  • Patient living in a nursing home or going back home after hospitalization.

Exclusion criteria

  • The subject is participating in another category I interventional study.
  • The subject is in an exclusion period determined by another study.
  • The subject is under safeguard of justice.
  • It is not possible to give the patient (or his/her trusted-person) informed information.
  • Palliative care

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Open label
Primary purpose
Other

Study locations

France · 4 centers
  • Chu de Grenoble — Grenoble
  • CHU de Montpellier — Montpellier
  • Nimes University Hospital — Nîmes
  • CHU de Toulouse — Toulouse

Identifiers

NCT: NCT03827031 · NIMAO/2017-02/JMK-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗